SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Endocrinology · 01.12.2021 · 162 (12)
DOI: 10.1210/endocr/bqab157 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 03.08.2021. Verfasst von Moein Ala. Beteiligte Einrichtung: School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 264 Literaturangaben.
Abstract (Originalsprache)
Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted tubule to decrease blood sugar. Several animal studies revealed that SGLT-2 is profoundly involved in the inflammatory response, fibrogenesis, and regulation of numerous intracellular signaling pathways. Likewise, SGLT-2 inhibitors markedly attenuated inflammation and fibrogenesis and improved the function of damaged organ in animal studies, observational studies, and clinical trials. SGLT-2 inhibitors can decrease blood pressure and ameliorate hypertriglyceridemia and obesity. Likewise, they improve the outcome of cardiovascular diseases such as heart failure, arrhythmias, and ischemic heart disease. SGLT-2 inhibitors are associated with lower cardiovascular and all-cause mortality as well. Meanwhile, they protect against nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, acute kidney injury, and improve micro- and macroalbuminuria. SGLT-2 inhibitors can reprogram numerous signaling pathways to improve NAFLD, cardiovascular diseases, and renal diseases. For instance, they enhance lipolysis, ketogenesis, mitochondrial biogenesis, and autophagy while they attenuate the renin-angiotensin-aldosterone system, lipogenesis, endoplasmic reticulum stress, oxidative stress, apoptosis, and fibrogenesis. This review explains the beneficial effects of SGLT-2 inhibitors on NAFLD and cardiovascular and renal diseases and dissects the underlying molecular mechanisms in detail. This narrative review explains the beneficial effects of SGLT-2 inhibitors on NAFLD and cardiovascular and renal diseases using the results of latest observational studies, clinical trials, and meta-analyses. Thereafter, it dissects the underlying molecular mechanisms involved in the clinical effects of SGLT-2 inhibitors on these diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
ORCID-Profile: Moein Ala
Zitieren
APA
Ala, M. (2021). SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology, 162(12). https://doi.org/10.1210/endocr/bqab157
Vancouver
Ala M. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology. 2021;162(12). doi:10.1210/endocr/bqab157
BibTeX
@article{Ala2021,
author = {Ala, Moein},
title = {SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD},
journal = {Endocrinology},
year = {2021},
volume = {162},
number = {12},
doi = {10.1210/endocr/bqab157}
}
EUVIMED